CoreAge Rx / Spot On
HYDROQUINONE · KOJIC ACID · NIACINAMIDE
Hydroquinone, kojic acid and niacinamide — three complementary routes to the same pigment, with the strongest depigmenting agent in general use at the centre of it. Two things the page leaves out and you should insist on: the hydroquinone percentage, and a stop date. This is a cycled therapy.
Worth buying for a specific person with a specific problem. Read who.
ASSESSED ON 75% OF THE MODEL. 2 CRITERIA LEFT UNSCORED — SEE SCORING FOR WHY.
Get the hydroquinone percentage and an agreed stop date before you start. This is a cycled therapy, not a standing order.
The verdict
The construction is the best-designed pigmentation stack we have assessed. Hydroquinone is the most effective topical depigmenting agent in general use and it is genuinely prescription-only in the United States, so the prescriber here is doing real work. Kojic acid inhibits the same rate-limiting enzyme by a different route. Niacinamide works at a different step altogether — it blocks the transfer of finished melanosomes into keratinocytes, so pigment that is made never reaches the surface — and it damps the irritation hydroquinone causes, which on pigmented skin is itself a cause of pigment.
The instructions are right as well, and they are not trivial ones. The page insists on daily sunscreen, which is not optional when you are removing the skin's own defence, and it says to apply to affected areas only — correct for spot treatment, and it happens to limit treated area, which is one of the named risk factors for exogenous ochronosis.
What the page does not give is the number. Hydroquinone is described as 'prescription-strength', which is a phrase rather than a concentration. Conventional prescription hydroquinone is 4%; compounded hydroquinone is dispensed from 3% to 12%, and the systematic review literature on ochronosis finds reported cases clustering above 4%. Ask for the percentage in writing. It is the figure that decides both how fast this works and what you are watching for.
And treat it as a course, not a subscription. Hydroquinone is conventionally used for two to three months and then cycled off, with prolonged use beyond about three months a named risk factor for ochronosis. This is sold as a rolling monthly plan with no duration on the page, which puts the stop date in your hands: agree one with the prescriber at the outset, and diarise the review. Do that and this is a good treatment. Leave it to the billing and it is not.
- Hydroquinone is the most effective topical depigmenting agent in general use, and genuinely prescription-only in the US.
- Three complementary pigment pathways — two tyrosinase inhibitors plus a melanosome-transfer blocker — is a well-designed stack.
- Niacinamide works at a different step from the other two and also damps hydroquinone's irritation.
- The page correctly insists on daily sunscreen and warns against excess sun exposure, which is essential for any pigmentation treatment.
- 'Apply to affected areas only' is the right instruction and limits treated area, one of the named ochronosis risk factors.
- The prescriber requirement is legitimate, and the intake, the compounding and delivery are included in the price.
- Hydroquinone concentration replaced with the phrase 'prescription-strength'.
- No duration or cycling guidance for a drug conventionally used in two-to-three-month courses.
- Sold as a rolling subscription, so the stop date is left to the buyer to enforce.
- No mention of exogenous ochronosis anywhere on the page.
- No side effects listed at all.
- Kojic acid concentration unpublished, despite contact dermatitis being its recognised primary risk.
- No antioxidant system or packaging described, for an active that oxidises readily.
- Most expensive of the company's five skincare products, with no container size published.
Every active, assessed
- HydroquinoneNOT PUBLISHED — 'PRESCRIPTION-STRENGTH'
Tyrosinase inhibitor — the most effective topical depigmenting agent in use
- BENCHMARK
- 4% is conventional prescription strength; ochronosis reports cluster above 4%
- ASSESSMENT
- The right drug for the indication and a legitimate reason for a prescriber. Its concentration determines both its speed and its risk profile, and a phrase is not a number — compounded hydroquinone is dispensed anywhere from 3% to 12%. Get the figure in writing before the first tube arrives.
- Kojic AcidNOT PUBLISHED
Tyrosinase inhibitor — a second, independent route to the same enzyme
- BENCHMARK
- EU scientific opinion holds it safe as a skin-lightening agent up to 0.7% in the final product
- ASSESSMENT
- A sensible complement to hydroquinone, hitting the same enzyme by a different route. Contact dermatitis is its recognised primary risk and it is the most common sensitiser of the three, so ask for its concentration too — particularly if you have reacted to it before.
- NiacinamideNOT PUBLISHED
Blocks melanosome transfer to keratinocytes; anti-inflammatory
- BENCHMARK
- 2%–5% is the evidenced range
- ASSESSMENT
- The cleverest choice in the formula, because it works on transfer rather than synthesis — a different step in the pathway from the other two — and it damps the irritation hydroquinone causes. Worth confirming it is at 2% or above.
| ACTIVE | CONC. | BENCHMARK | ASSESSMENT |
|---|---|---|---|
| HydroquinoneTyrosinase inhibitor — the most effective topical depigmenting agent in use | NOT PUBLISHED — 'PRESCRIPTION-STRENGTH' | 4% is conventional prescription strength; ochronosis reports cluster above 4% | The right drug for the indication and a legitimate reason for a prescriber. Its concentration determines both its speed and its risk profile, and a phrase is not a number — compounded hydroquinone is dispensed anywhere from 3% to 12%. Get the figure in writing before the first tube arrives. |
| Kojic AcidTyrosinase inhibitor — a second, independent route to the same enzyme | NOT PUBLISHED | EU scientific opinion holds it safe as a skin-lightening agent up to 0.7% in the final product | A sensible complement to hydroquinone, hitting the same enzyme by a different route. Contact dermatitis is its recognised primary risk and it is the most common sensitiser of the three, so ask for its concentration too — particularly if you have reacted to it before. |
| NiacinamideBlocks melanosome transfer to keratinocytes; anti-inflammatory | NOT PUBLISHED | 2%–5% is the evidenced range | The cleverest choice in the formula, because it works on transfer rather than synthesis — a different step in the pathway from the other two — and it damps the irritation hydroquinone causes. Worth confirming it is at 2% or above. |
Scoring
- EVIDENCE FOR THE ACTIVEWEIGHT 30%93/100
Hydroquinone is grade-A for hyperpigmentation and the reference against which every other depigmenting agent is measured; niacinamide has real support at a different step in the pathway; kojic acid has modest support at the same enzyme by another route. Three complementary pathways, one of them anti-inflammatory, is the best-designed pigment stack in the register. Short of the top because no concentration is published and no data is cited for the finished product.
- FORMULATION INTEGRITYWEIGHT 20%87/100
The pathway logic is excellent and the use instructions match it — spot application, daily sunscreen, avoid broken skin. Marked down because hydroquinone oxidises readily, which makes the antioxidant system and the packaging central to whether the cream still works in month two, and neither is described. No vehicle or pH is published either.
- DISCLOSUREWEIGHT 15%64/100
The weakest criterion here and the reason this is a conditional rather than an outright recommendation. A drug whose risk profile is defined by its concentration has that concentration replaced by an adjective. There is no duration or cycling guidance for a therapy with a built-in stop date, no mention of ochronosis, no side effects, no INCI and no container size. The directions themselves are specific and correct, which is what keeps this criterion off the floor.
- TOLERANCE IN USEWEIGHT 15%NOT ASSESSED
Not assessed, and not assessable in principle — tolerance to hydroquinone and to kojic acid is a function of concentration, and neither concentration is published.
- TEXTURE & WEARWEIGHT 10%NOT ASSESSED
Not assessed. Requires the product in hand over the full trial window.
- COST PER APPLICATIONWEIGHT 10%82/100
$660 a year, the most expensive of this company's five skincare products, with the prescriber, the compounding and delivery included. It contains a genuine prescription drug that cannot be bought over the counter in the US at all, so the premium has a real basis. Held back because no container size is published and because a cycled therapy billed monthly asks you to manage the stop date yourself.
What it is
Spot On is a compounded topical for dark spots, uneven tone and post-acne marks, sold by CoreAge Rx at $54.99 a month — the most expensive of their five skincare products. It names three actives: hydroquinone, kojic acid and niacinamide. It publishes a concentration for none of them, describing the hydroquinone only as 'prescription-strength'.
The stack is well built
Pigmentation is worth attacking from more than one direction, and this formula does. Hydroquinone and kojic acid both inhibit tyrosinase, the rate-limiting enzyme in melanin synthesis, by different routes. Niacinamide works at a completely different step — it blocks the transfer of finished melanosomes from melanocytes into keratinocytes, so pigment that is made never reaches the surface.
Niacinamide is also the right companion for the other two, because hydroquinone irritates and irritation on pigmented skin is how you produce more pigment. Three pathways, one of them anti-inflammatory, is a considered design.
The instructions are good too. Daily sunscreen is not optional with any depigmenting agent — you are removing the skin's own UV defence — and the page says so. So does 'apply to affected areas only', which is correct for spot treatment and happens to limit one of the named risk factors for ochronosis.
'Prescription-strength' is not a concentration
Conventional prescription hydroquinone is 4%. The old over-the-counter ceiling in the US was 2%, withdrawn in 2020. And compounded hydroquinone is dispensed far above that — we have reviewed products at 3%, 6% and 12% from a single competitor's catalogue.
The reason the number matters is exogenous ochronosis: a paradoxical blue-black darkening of treated skin that is difficult to reverse. The systematic review literature finds reported cases clustering at concentrations above 4%, with prolonged use and large treated areas as the co-factors.
Every one of these is a real compounded strength. The phrase on the page covers all of them, which is why the number belongs in writing before you start.
A buyer told they are getting 'prescription-strength' hydroquinone cannot tell whether they are on a routine 4% course or something three times that. Those are different products with different monitoring requirements, and the person applying it every night is the one who most needs to know which. It is one line in a reply to the intake, and you are entitled to it.
This is a cycled drug, and a subscription is not
Hydroquinone is not a maintenance product. It is conventionally used for a limited period — on the order of two to three months — and the standard dermatological approach is to cycle it: three to four months of use, then a break of two to three months before resuming if needed. Prolonged use beyond about three months is one of the named risk factors for ochronosis.
This product is sold as a monthly subscription. No duration is stated on the page, no cycling is described, and there is no review point built into the commercial arrangement. The default behaviour of a subscription is continuation; the default requirement of hydroquinone is a stop. That mismatch is manageable, but only if you manage it — agree a stop date at the intake, put it in your calendar, and treat the renewal as something you actively decide rather than something that happens.
The conventional course, the point at which risk rises, and the commercial structure it is sold through.
The prescriber is unlikely to be unaware of this. Physicians who prescribe hydroquinone generally know how it is used, and the intake may well set a duration we cannot see. But the page is what a buyer reads before committing, and the page says nothing — no course length, no cycling, no mention of ochronosis, and no side effects of any kind. One sentence would close it.
Two smaller gaps worth naming
Kojic acid is the most common sensitiser in this formula. Contact dermatitis is its recognised primary risk, and European scientific opinion holds it safe as a skin-lightening agent up to 0.7% in the finished product. What is in this cream is not published, and neither is any warning about sensitisation.
The other gap is stability. Hydroquinone oxidises readily — that is why it discolours, and an oxidised hydroquinone is an inactive one. When we reviewed a competitor's hydroquinone product we gave it genuine credit for a deliberate antioxidant system and opaque airless packaging, because those are the things that decide whether the product still works in week eight. Nothing of the kind is described here.
If you are considering it
- Ask for the hydroquinone percentage in writing before you subscribe. Do not accept 'prescription-strength'.
- Agree a stop date at the outset, and ask what the cycling plan is after it.
- Ask the kojic acid concentration, particularly if you have reacted to it before.
- Ask what packaging it ships in and whether the formula contains an antioxidant to slow oxidation.
- Ask the container size so you can work out the real cost per application.
- Treat defined spots, not your whole face. Large treated area is a named risk factor.
- Wear broad-spectrum sunscreen every single day. Without it this treatment works against itself.
- Stop immediately and seek advice if the treated skin darkens, greys or takes on a bluish cast rather than lightening.
Where we stand
The formula is the best-designed pigmentation treatment in the register. Hydroquinone is the strongest depigmenting agent in general use, kojic acid attacks the same enzyme by another route, and niacinamide works at a different step in the pathway while damping the irritation the other two cause. The prescriber requirement is real, the sunscreen instruction is right, and 'affected areas only' is the correct way to use it.
It is an 84 rather than higher because of two things the page leaves to the buyer, and both are cheap to fix. The hydroquinone concentration is given as an adjective rather than a number, and a therapy with a built-in stop date is sold through an arrangement whose default is continuation, with no ochronosis note and no cycling guidance anywhere on the page.
Get the percentage in writing, agree a stop date, treat discrete spots rather than a whole face, and wear sunscreen every day. Do that and this is a good treatment. The remedy on the company's side is one percentage, one course length, one sentence about cycling and one about ochronosis — four lines of copy that would cost them nothing they should want to keep.
Who this is for
- Someone with defined dark spots or post-inflammatory marks who has obtained the hydroquinone concentration in writing and agreed a stop date with the prescriber.
- Someone who will genuinely wear daily broad-spectrum sunscreen, without which any depigmenting treatment is self-defeating.
- Someone treating discrete areas rather than resurfacing a whole face indefinitely.
- You have not been told the hydroquinone percentage. It is the number that determines the risk.
- You intend to use it continuously. Hydroquinone is a cycled therapy, not a permanent product.
- You have a deeper skin tone and will not be reviewed in person — reported ochronosis risk is concentrated there.
- You are pregnant or breastfeeding.
- You will not use sunscreen daily.
- You have previously reacted to kojic acid — it is the most common sensitiser of the three and its level here is unstated.
Get the hydroquinone percentage and an agreed stop date before you start. This is a cycled therapy, not a standing order.
This is an editorial assessment of published information about a prescription product. It is not a diagnosis, not a prescription and not a substitute for your own prescriber. Hydroquinone and tretinoin are drugs. Decisions about them belong with a clinician who has seen your skin.
Sources
- S-01CoreAge Rx — Spot On product page Price, the three named actives without concentrations, 'prescription-strength' framing, directions, and the absence of duration guidance, side effects, INCI, size or clinical data.
- S-02Hydroquinone — StatPearls Conventional strengths, typical two-to-three-month course length and adverse effects.
- S-03Ishack et al. — exogenous ochronosis associated with hydroquinone: a systematic review Reported ochronosis cases cluster above 4%, with prolonged use and large treated area as co-factors.
- S-04DermNet NZ — hydroquinone Clinical guidance on duration, cycling and monitoring.
- S-05SCCS opinion on kojic acid (SCCS/1637/21) European scientific opinion on safe use of kojic acid as a skin-lightening agent in cosmetic products.